TBS-2025 Cleared to Enter Post-Menin mutNPM1 AML
FDA issued a “study may proceed” notice for a Phase Ib study of TBS-2025, a VISTA-inhibiting monoclonal antibody, in relapsed or refractory acute myeloid leukemia with mutant NPM1 after failure of or relapse on…
